|
Contents |
|
|
|
|
|
Astrocytomas
|
|
|
|
Snelling
L, Miyamoto CT, Bender H, Brady
LW, Steplewski Z, Class R, Emrich J, Rackover MA
Epidermal
growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in
the adjuvant treatment of high-grade astrocytomas
Hybridoma
1995 Apr;14(2):111-4
|
|
|
CNS
Tumors |
 
|
|
|
I.
Cokgor, G.
Akabani, A. Friedman, R. Coleman, M. Zalutsky, R. McLendon, S. Bigner, Z.
Xiao-Guang, C. Pegram, C. Wikstrand, J. Herndon, J. Provenzale, H. Friedman, D. Bigner
Results of a Phase II Trial in the Treatment of
Recurrent Patients with Brain Tumors Treated with Iodine 131 Anti-Tenascin
Monoclonal Antibody 81C6 Via Surgically Created Resection Cavities
ASCO
Proceedings, 2000 Annual Meeting, Abstract No. 628
|
|
David A. Reardon, G. Akabani, J. Dowell, Allan Friedman, Henry Friedman,
James Herndon, Roger McLendon, Jennifer Quinn, Jeremy Rich, James Vredenburgh,
Kara Penne, John Sampson, Timothy Shafman, Terrance Wong, R. Coleman, Michael
Zalutsky, Darell Bigner
Results of a phase II trial with iodine 131-labeled murine
antitenascin monoclonal antibody 81c6 (m81c6) via surgically created resection
cavities in the treatment of patients with recurrent malignant brain tumors
Proceedings of the AACR, Volume 45, March 2004. Abstract
Number: 5237
|
|
David
Reardon, Gamal
Akabani, Allan Friedman, Henry Friedman, James Herndon II, Ilkcan Cokgor, Roger
McLendon, Jennifer Quinn, Jeremy Rich, Kara Penne, John Sampson, Timothy
Shafman, Terence Wong, Michael Zalutsky, Darell D Bigner
Phase
I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6
treatment of patients with newly diagnosed malignant brain tumors following
external beam radiotherapy
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. 2113
|
|
T.
Shafman,
D. A. Reardon, G. Akabani, A. Friedman, H. S. Friedman, J. Sampson, T.
Wong, X.-G. Zhao, M. Zalutsky, D. D. Bigner
Delivering
a targeted radiation boost dose of 44Gy to the resection cavity perimeter
of patients with newly diagnosed malignant brain tumors via an
individualized dose of 131-iodine labeled murine antitenascin monoclonal
antibody 81C6: Preliminary results of a phase II trial
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003
|
|
|
Cancer
Research |
|
|
|
Otto
C. Boerman, PhD, Frank G. van Schaijk, MSc, Wim J.G. Oyen, MD, PhD and Frans
H.M. Corstens, MD
Pretargeted Radioimmunotherapy of Cancer: Progress
Step by Step
Journal of Nuclear Medicine Vol. 44 No. 3 400-411 (PDF Full Text)
|
|
Cremonesi M, Ferrari M, Chinol M, Bartolomei M, Stabin MG,
Sacco E, Fiorenza M, Tosi G, Paganelli G
Dosimetry
in radionuclide therapies with 90Y-conjugates: the IEO experience
Q J Nucl Med. 2000 Dec; 44(4): 325-32
|
|
Seigo
Kinuya, MD, Atsuhiro Kawashima, MD, Kunihiko Yokoyama,
MD, Kiyoshi Koshida, MD,
Shota Konishi, MD, Naoto Watanabe, MD, Noriyuki Shuke,
MD, Hisashi Bunko, MD, Takatoshi Michigishi, MD
and Norihisa Tonami, MD
Cooperative Effect of Radioimmunotherapy and Antiangiogenic Therapy with
Thalidomide in Human Cancer Xenografts
Journal of Nuclear Medicine Vol. 43 No. 8 1084-1089, 1 August 2002
.JPG) Abstract |
.png) Full Text |
.png) Reprint
|
|
Larson SM
Clinical
radioimmunodetection, 1978-1988: overview and suggestions for standardization of
clinical trials
Cancer Res. 1990 Feb 1; 50(3 Suppl): 892s-898s
|
|
Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C,
Bartolomei M, Orsi F, De Cicco C, Macke HR, Chinol M, de Braud F.
Receptor-mediated
radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide
Eur
J Nucl Med 2001 Apr;28(4):426-34
|
|
|
Glioblastoma |
|
|
|
M. A. Badruddoja, D. A. Reardon, G.
Akabani, A. H. Friedman, H. S. Friedman, J. N. Rich, J. A. Quinn, K. Penne, J.
J. Vredenburgh, D. D. Bigner
Phase II trial of iodine 131-labeled murine
anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection
cavity in the treatment of patients with recurrent malignant brain tumors
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1569
|
|
Mirco
Bartolomei MD,
Chiara
Grana MD,
Chiara
Mazzetta Bsc, Giulio
Maira MD, Daria
Handkiewicz-Junak MD,
Carmelo
Sturiale MD,
Lisa
Bodei MD, Gaetano
Villa MD, Paola
Rocca MD,
Giovanni
Paganelli MD
Combined Treatment of Glioblastoma Patients
with Locoregional Pre-targeted 90Y-Biotin Radioimmunotherapy and
Temozolomide
The Quarterly Journal of Nuclear Medicine, 2004, Vol. 48, No. 3, September
|
|
Amerigo Boiardi,
Mirco Bartolomei, Antonio Silvani,
Marica Eoli, Andrea Salmaggi, Elena Lamperti,
Ida Milanesi, Andrea Botturi, Paola Rocca,
Lisa Bodei, Giovanni Broggi and
Giovanni Paganelli
Intratumoral delivery of mitoxantrone in association with 90-Y
radioimmunotherapy (RIT) in recurrent glioblastoma
Journal of Neuro-Oncology, Vol 72, Number 2, April, 2005, Pages 125-131, DOI:
10.1007/s11060-004-1497-5, Online Date May 31, 2005
|
|
Heute
D, Kostron H, von Guggenberg E, Ingorokva S, Gabriel M, Dobrozemsky G,
Stockhammer G, Virgolini IJ
Response
of recurrent high-grade glioma to treatment with (90)Y-DOTATOC
J Nucl Med. 2010
Mar;51(3):397-400. Epub 2010 Feb 11
Abstract
|
|
Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE,
Jenrette JM, Cohen SC, Black P, Brady LW.
A Phase II study of anti-epidermal growth factor receptor
radioimmunotherapy in the treatment of glioblastoma multiforme
J Neurosurg. 2010 Mar 26;. [Epub ahead of print]
Abstract
|
|
J. J. Vredenburgh, D.
Reardon, G. Akabani, A. Friedman, H.
Friedman, R. McLendon, J. Quinn, J.
Rich, M. Zalutsky and D. Bigner
Results of a
phase II study of 131 Iodine-labeled anti-tenascin murine monoclonal
antibody 81C6 (m81C6) administered to deliver a targeted radiation boost
dose of 44 Gy to the surgically created cystic resection cavity perimeter
in the treatment of patients with newly diagnosed primary and metastatic
brain tumors
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1510
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1510
|
|
|
Gliomas |
|
|
|
Bigner DD,
Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon
RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE 2nd, Vick NA,
Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR
Iodine-131-labeled
antitenascin monoclonal antibody 81C6 treatment of patients with recurrent
malignant gliomas: phase I trial results
J Clin Oncol. 1998 Jun; 16(6): 2202-12
|
|
A. Casaco, G. López, R. Fernandez,
L. Diaz, A. Perera, J. Batista, R. Leyva, Y. Peña, J. A. Rodriguez, I. Garcia
Loco-regional radioimmunotherapy of high grade
malignant gliomas using the humanized monoclonal antibody, h-R3, labeled with
188-Re
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.2530
|
|
Cokgor I,
Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner
SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE
2nd, Provenzale JM, Zalutsky MR, Bigner DD
Phase
I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6
treatment of patients with newly diagnosed malignant gliomas
J Clin Oncol. 2000 Nov 15; 18(22): 3862-72
|
|
Emrich
JG, Brady LW, Quang TS, Class R, Miyamoto C, Black P, Rodeck U
Radioiodinated
(I-125) monoclonal antibody 425 in the treatment of high grade glioma patients:
ten-year synopsis of a novel treatment
Am J Clin Oncol 2002 Dec;25(6):541-6
|
|
C. Goetz,
P. Riva, G. Poepperl, F.J. Gildehaus, A.
Hischa, K.
Tatsch, H.-J.
Reulen
Locoregional
radioimmunotherapy in selected patients with malignant glioma: experiences, side
effects and survival Arial
Journal of Neuro-Oncology,
62 (3): 321-328, May
2003
|
|
Chiara Grana, Marco Chinol, Chris
Robertson, Mirco Bartolomei, Tommaso M De Pas, Giovanni Paganelli
The
role of 3-step radioimmunotherapy (RIT) as adjuvant treatment in malignant
gliomas
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No. 2084
|
|
Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C,
Fiorenza M, Gatti M, Caliceti P, Paganelli G.
Pretargeted
adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients:
a pilot study
Br
J Cancer 2002 Jan 21;86(2):207-12
|
|
Hopkins K, Chandler C, Bullimore J, Sandeman D, Coakham H, Kemshead JT
A pilot
study of the treatment of patients with recurrent malignant gliomas with
intratumoral yttrium-90 radioimmunoconjugates
Radiother
Oncol. 1995 Feb; 34(2): 121-31
|
|
Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi
G, Maira G, Sturiale C, Grana C, Prisco G, Gatti M, Caliceti P, Chinol M
Pre-targeted
locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I
study and preliminary therapeutic results
Cancer Biother Radiopharm. 2001 Jun; 16(3): 227-35
|
|
Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F,
Robertson C, Zurrida S, Casadio C, Zoboli S, Siccardi AG, Veronesi U.
Antibody-guided
three-step therapy for high grade glioma with yttrium-90 biotin
Eur
J Nucl Med 1999 Apr;26(4):348-57
|
|
|
Reardon DA, Zalutsky MR, Akabani G, Coleman RE,
Friedman AH, Herndon Ii JE, McLendon RE, Pegram CN, Quinn JA, Rich JN,
Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM,
Wong TZ, Zhao XG, Friedman HS, Bigner DD
A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a
44-Gy resection cavity boost
Neuro Oncol. 2008 Feb 20; [Epub ahead of print]
Abstract
|
|
Reardon DA, Akabani G, Coleman RE,
Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN,
Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand
CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD
Phase II trial of murine (131)I-labeled antitenascin
monoclonal antibody 81C6 administered into surgically created resection cavities
of patients with newly diagnosed malignant gliomas
J Clin Oncol 2002 Mar 1;20(5):1389-97
|
|
P.
Riva, M. Santimaria, M. Casi, M. Adamo, R. Nada, N. Inzaga, Maurizio
Bufalini
Loco-regional
radioimmunotherapy of malignant glioma by means of a humanised antibody hR3
(raised against epidermal growth factor receptors) labelled with Y-90
39th ASCO Annual
Meeting. Chicago, IL. May 31-June 3, 2003
|
|
Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo
M
Role
of nuclear medicine in the treatment of malignant gliomas: the locoregional
radioimmunotherapy approach
Eur J Nucl Med. 2000
May; 27(5): 601-9
|
|
Riva P, Franceschi G, Frattarelli M, Lazzari S, Riva N,
Giuliani G, Casi M, Sarti G, Guiducci G, Giorgetti G, Gentile R, Santimaria M,
Jermann E, Maeke HR.
Loco-regional
radioimmunotherapy of high-grade malignant gliomas using specific monoclonal
antibodies labeled with 90Y: a phase I study
Clin Cancer Res. 1999 Oct; 5(10 Suppl): 3275s-3280s
|
|
Pietro Riva, Giancarlo Franceschi, Massimo
Frattarelli, Nada Riva,
Graziano Guiducci, Anna Maria Cremonini, Graziano Giuliani, Michela Casi,
Rossella Gentile, Annti A. Jekunen, Kalevi J. A. Kairemo
131I Radioconjugated Antibodies for the Locoregional Radioimmunotherapy of
High-grade Malignant Glioma: Phase I and II Study
Acta Oncologica, Volume 38, Number 3/May 18, 1999, 351 - 359
Abstract |
Reprint
|
|
Patel
Sunil, Ke Spicer, Pamel
VanTassel, Stephe Haines, Leonni Gordon, Ar Frankel,
Jami Oliver
Phase I Results of Intra-Tumoral Infusion of I-131
ch-TNT-1/B in the Treatment of Recurrent Malignant Gliomas
ASCO
Proceedings, 1999 Annual Meeting, Abstract No. 550
|
|
Zalutsky
MR, Moseley RP, Coakham HB, Coleman RE, Bigner DD
Pharmacokinetics
and tumor localization of 131I-labeled anti-tenascin monoclonal antibody
81C6 in patients with gliomas and other intracranial malignancies
Cancer Res. 1989 May 15; 49(10): 2807-13
|
|
|
References |
|
|
|
Goodwin DA
Pharmacokinetics
and antibodies
J Nucl Med. 1987 Aug; 28(8): 1358-62
Abstract |
Reprint
|
|
Paganelli G, Chinol M
Radioimmunotherapy:
is avidin-biotin pretargeting the preferred choice among pretargeting methods?
Eur J Nucl Med Mol Imaging. 2003 May; 30(5): 773-6. Epub 2003 Jan 30
|
|
